From the Editor-in-Chief

The U.S. health care system must adapt to the needs of cancer survivors.

by William G. Nelson, MD, PhD

Cancer patients are increasingly receiving treatments guided by the molecular characteristics of their cancer cells. But patients may have unequal access to testing and targeted therapies.

by Kate Yandell

Forward Look

Cell and molecular biologist Ashani Weeraratna discusses how older patients respond to immunotherapy.

by Sue Rochman

Forward Look

A study suggests high-risk patients do not need chemotherapy.

by Stephen Ornes

Forward Look

Lung cancer deaths are set to surpass breast cancer deaths in many regions.

by Cameron Walker

Forward Look

Drugs approved through this pathway may have limited evidence.

by Lindsey Konkel

New tools are being integrated into the research process to ease patients' access to clinical trials and improve their experience.

by Bradley Jones

Forward Look

Off-the-shelf equivalents to CAR-T cell therapy are emerging.

by Bradley Jones

Studies presented at the 2018 San Antonio Breast Cancer Symposium investigate when patients with early-stage breast cancer or precancerous breast conditions benefit from receiving less intense treatment.

by Kate Yandell

Medical oncologist and sarcoma specialist George D. Demetri explains the significance of the recent approval of the oral drug Vitrakvi based on tumor genetics.

by Anna Azvolinsky